Eli Lilly (LLY)
(Delayed Data from NYSE)
$891.68 USD
+46.37 (5.49%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $892.28 +0.60 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 61 - 80 ( 434 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotechnology- Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 24.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 21123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended January 13.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 1123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 122122
Provider: Stock Traders Daily
Analyst: Research Department